Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus paclitaxel/carboplatin in pMMR endometrial cancer (Phase II, single arm)
ChiCTR2500110086Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in endometrial cancer (EC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Started Sep 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2500110086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110086.